Promising Results for Enfortumab Vedotin in Neoadjuvant Treatment of Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

This MEDtalk provides background information about muscle-invasive bladder cancer, the standard treatment approaches, and the challenges of cisplatin-ineligible patients. Dr. Srikala Sridhar
describes the study design and the results of Study EV-103 Cohort L, including the pathological complete response rate and safety profile of the treatment with enfortumab vedotin in the neoadjuvant setting.